SCHEMBL7148734

SCHEMBL7148734

C=CCOC(=O)NC(CC)(CC(=O)O)c1cccc(NS(=O)(=O)c2cccc(N)c2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.43
HTR6 P50406 2/20 0.40
GAA P10253 1/20 0.39
PKM P14618 3/20 0.36
KMT2A Q03164 2/20 0.35
MAPT P10636 3/20 0.35
LMNA P02545 3/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 2/20 0.35
HIF1A Q16665 1/20 0.34
CA1 P00915 2/20 0.34
CA2 P00918 2/20 0.34
RAB9A P51151 1/20 0.34
TP53 P04637 1/20 0.34
HDAC3 O15379 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC7 Q8WUI4 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC10 Q969S8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7150464 0.87 KMT2A (0.45) HTR6PKMKMT2AMAPTLMNA
SCHEMBL7147943 0.86 MAPT (0.43) POLBGAAKMT2AMAPTLMNA
SCHEMBL3840584 0.73 POLB (0.39) POLBHTR6GAAPKMKMT2A
SCHEMBL7148744 0.73 HTR6 (0.43) POLBHTR6PKMKMT2AMAPT
SCHEMBL7150268 0.72 POLB (0.41) POLBHTR6GAAPKMKMT2A
SCHEMBL3809843 0.71 POLB (0.40) POLBHTR6PKMKMT2AMAPT
SCHEMBL28271796 0.65 HTR6 (0.83) POLBHTR6PKMKMT2ALMNA
SCHEMBL3841758 0.65 POLB (0.39) POLBHTR6PKMKMT2AMAPT
SCHEMBL14186065 0.64 ALDH1A1 (0.40) POLBGAAKMT2ALMNAMEN1
SCHEMBL13623013 0.64 POLB (0.56) POLBHTR6PKMKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1347783-A1 CONJUGATES OF INTEGRIN RECEPTOR ANTAGONISTS AND A CYTOSTATIC AGENT HAVING SPECIFICALLY CLEAVABLE LINKING UNITS Bayer Aktiengesellschaft (DE) 2003-10-01 EP disclosed
US-20020183256-A1 Cytostatic-integrin conjugates having specifically cleavable linking units BAYER AKTIENGESELLSCHAFT (DE) 2002-12-05 US disclosed
EP-1238678-A1 Enzyme-activated cytostatic conjugates with integrin ligands Bayer Aktiengesellschaft (DE) 2002-09-11 EP disclosed
WO-2002051444-A1 CONJUGATES OF INTEGRIN RECEPTOR ANTAGONISTS AND A CYTOSTATIC AGENT HAVING SPECIFICALLY CLEAVABLE LINKING UNITS BAYER AKTIENGESELLSCHAFT (DE) 2002-07-04 WO disclosed
EP-1219305-A1 Conjugates of integrin receptor antagonists and a cytostatic agent having specifically cleavable linking units Bayer Aktiengesellschaft (DE) 2002-07-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183256-A1 Cytostatic-integrin conjugates having specifically cleavable linking units ITGAV, ITGB3, ITGAL POLB 2115/4885HTR6 3289/4885GAA 499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.